Burak Y. Aktas - Publications

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Journal: Cancers

Published: May 12, 2026

The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 02, 2026

Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoid.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 04, 2026

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 01, 2025

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Journal: Nature communications

Published: June 01, 2025

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel.

Journal: Medicina (Kaunas, Lithuania)

Published: May 04, 2025

Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study.

Journal: Discover oncology

Published: April 02, 2025

Prognostic value of the StAN score in elderly small cell lung cancer.

Journal: Scientific reports

Published: March 19, 2025

Immune Checkpoint Molecule Expression, 9p24.1 Gene Alterations, and Tumor Microenvironment of Primary Central Nervous System Lymphomas and Their Clinical Relevance.

Journal: Applied immunohistochemistry & molecular morphology : AIMM

Published: February 10, 2025

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.

Journal: BMC cancer

Published: June 06, 2024

Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy.

Journal: Cancers

Published: February 12, 2024

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia.

Journal: Current oncology (Toronto, Ont.)

Published: September 21, 2023